Skip to main content

Corvus Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

CRVS$11.37+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

POWER OF ATTORNEY

Each person whose individual signature appears below hereby authorizes and appoints Richard A. Miller, M.D. and Leiv Lea and each of them, with full power of substitution and resubstitution, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agents or his substitute or substitutes may lawfully do or cause to be done by virtue thereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ RICHARD A. MILLER, M.D.​ ​President, Chief Executive Officer and Director​ ​ ​​
Richard A. Miller, M.D.​(Principal Executive Officer)​March 12, 2026
​​​​​
/s/ LEIV LEA​Chief Financial Officer​​
Leiv Lea​(Principal Financial and Accounting Officer)​March 12, 2026
​​​​​
/s/ IAN T. CLARK​Director​March 12, 2026
Ian T. Clark​​
​​​​​
/s/ LINDA S. GRAIS, M.D., J.D.​Director​March 12, 2026
Linda S. Grais, M.D., J.D.​​
​​​​​
/s/ DAVID MOORE​Director​March 12, 2026
Davis Moore​​
​​​​​
/s/ SCOTT W. MORRISON​Director​March 12, 2026
Scott W. Morrison​​
​​​​​
/s/ PETER THOMPSON, M.D.​Director​March 12, 2026
Peter Thompson, M.D.​​
​​​​​
/s/ RICHARD A. VAN DEN BROEK​Director​March 12, 2026
Richard A. van den Broek​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.